Status:
COMPLETED
Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma
Lead Sponsor:
Samsung Medical Center
Conditions:
Neuroblastoma
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCR in children with high-risk neuroblastoma. In the present study, a single arm trial of tandem HDCT/ASCR will be ca...
Detailed Description
The prognosis of high-risk neuroblastoma after conventional chemoradiotherapy is generally poor. Therefore, a strategy using high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) has been...
Eligibility Criteria
Inclusion
- Patients with high-risk neuroblastoma
- Patients with intermediate-risk neuroblastoma if gross tumor remained after surgery
Exclusion
- Patients with progressive disease before high-dose chemotherapy
- Patients whose parents want to stop or change the planned treatment
- Patients with organ toxicities of NCI grade \>2 before high-dose chemotherapy
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00793845
Start Date
August 1 2008
End Date
January 1 2018
Last Update
September 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea